{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tuberculosis/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"72382f51-4bac-5de9-9caf-c6f16082070d","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field 44fe5d48-f1f3-486b-9a16-a9cf00c7aaf6 --><h2>What is the prognosis?</h2><!-- end field 44fe5d48-f1f3-486b-9a16-a9cf00c7aaf6 -->","summary":"","htmlStringContent":"<!-- begin item a7c01c29-6571-455e-916a-a9cf00c7aab0 --><!-- begin field 1fe20113-2e49-4af7-8ad3-a9cf00c7aaf6 --><p><strong>The prognosis of tuberculosis (TB) varies according to the geographical burden of disease, drug resistance patterns, the person's risk factors, and treatment uptake </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">WHO, 2018a</a>]<strong>.</strong></p><ul><li>If untreated, active TB is a slowly progressive disease in most people, which may be potentially fatal, particularly if the diagnosis is delayed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>].<ul><li>A systematic review found the 10-year weighted-mean case fatality rates were 70% for untreated smear-positive (infectious) TB, and were estimated to be 20% for smear-negative TB. It found the duration of disease from symptom onset to cure or death was about 3 years, and appeared to be similar for smear-positive and smear-negative cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Tiemersma, 2011</a>].</li></ul></li><li>Increasing age, more extensive disease, and HIV co-infection are associated with a worse prognosis, recurrent infection and/or reinfection, and increased mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Dheda, 2016</a>].<ul><li>Globally, the proportion of people with TB and HIV co-infection who died during treatment was 11%, similar to previous years and about three times the level among all new and relapse cases of TB (4%).</li></ul></li><li>Multidrug-resistant TB has a poorer prognosis than fully drug-susceptible TB, and risk factors include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">Millard, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">NICE, 2016</a>]:<ul><li>Previous TB drug treatment (especially if there is a history of poor adherence or treatment failure).<ul><li>In 2017, the proportion of people with multidrug-resistant or rifampicin-resistant TB was higher among people with a previous diagnosis of TB compared with those without (6.6% versus 1.5% of cases) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2018a</a>].</li></ul></li><li>Contact with a known index case of multidrug-resistant TB.</li><li>Country of origin with a high proportion of multidrug-resistant new TB cases.<ul><li>Between 2013 and 2017, the majority of people with extensively drug-resistant TB in England were born outside the UK, predominantly coming from Lithuania, India, and Romania [<a class=\"bibliography-reference internal-reference\" href=\"/topics/tuberculosis/references/\">PHE, 2018a</a>].</li></ul></li></ul></li></ul><!-- end field 1fe20113-2e49-4af7-8ad3-a9cf00c7aaf6 --><!-- end item a7c01c29-6571-455e-916a-a9cf00c7aab0 -->","topic":{"id":"c8d06469-2b39-5daa-bda8-b076b7204860","topicId":"c1897d19-8ea9-40e5-84a7-c45a80747a3e","topicName":"Tuberculosis","slug":"tuberculosis","lastRevised":"Last revised in January 2019","chapters":[{"id":"7216c242-e6e9-5726-9bad-d4bbd4071072","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aa25f749-53e8-5ff7-a3be-ddfd9f824295","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c40ce5c-b940-5a6e-a414-cb379ae5f2c1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5b948ae0-2789-5df7-b344-42eb6ae4054d","slug":"changes","fullItemName":"Changes"},{"id":"706989f4-45e1-583c-bcbc-d08833e25634","slug":"update","fullItemName":"Update"}]},{"id":"5edbfe3e-e825-5d79-a1d2-fa1b3b258467","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2e115c8b-8ca5-587b-bf34-83ddeeae2383","slug":"goals","fullItemName":"Goals"},{"id":"dbbfc2a1-e777-55e9-b654-44db5bf1efb4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bdce292e-6c5f-53df-a014-fc8432efa249","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1f5efb77-1619-5cf3-be88-86fd03247324","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f93c9e3-2eb5-5d68-bbc0-99b7ea53b835","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a028a0db-e900-5a0f-88ba-f333bcd824c9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c26e051a-e3f8-57b8-95af-985e9e93a3aa","slug":"definition","fullItemName":"Definition"},{"id":"2deaf55e-4677-569a-a2e0-a8748b44829f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f2d695cb-4d0e-5513-a7f3-01df45726347","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc328fb0-65a2-5d6a-94fe-0bfa42962928","slug":"complications","fullItemName":"Complications"},{"id":"72382f51-4bac-5de9-9caf-c6f16082070d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7e56c88f-1492-52ab-9f0b-cfc6b986db85","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b5294e44-2490-5ba7-8d81-0085ae3114a7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b90838b4-5d6d-57e8-aabd-afaad5a60e3f","slug":"investigations","fullItemName":"Investigations"},{"id":"8d7ee3e2-c863-574f-a042-172b8d909e84","slug":"screening","fullItemName":"Screening"},{"id":"a6c65c83-026b-50f1-b32d-5d28e8e7ae46","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"880c8c31-e325-5d4b-b4de-6ac05a1a9f94","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ab22745-718a-5096-a75f-2e6c874d6267","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"fd726cd9-2566-5903-9e38-d7333b140c5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3ac0b667-89b4-5934-98e1-938fd35e537f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3834823-1bb2-52a0-92c5-cb04316db808","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b2e2271f-aaf8-57a5-aba4-42de8a475bc5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e611555b-70b5-5ea6-8e53-5220621e1603","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdb64832-ab19-58f6-978e-d73fe8657b7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"200b04d2-7d10-5430-abe3-3802b135aea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74113d46-a800-5f0b-9d3d-096dc4137936","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"24cda0d7-3e0d-58d5-9229-0a15e99013c4","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}